Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

33.77 +0.01 (+0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 800
Open 33.77
Bid (Size) 33.62 (1,000)
Ask (Size) 36.51 (100)
Prev. Close 33.76
Today's Range 33.77 - 33.77
52wk Range 25.16 - 36.48
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
From Alkermes plc
Via Business Wire
News headline image
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
From Alkermes plc
Via Business Wire

Performance

YTD
+19.5%
+19.5%
1 Month
+22.1%
+22.1%
3 Month
+8.2%
+8.2%
6 Month
+9.6%
+9.6%
1 Year
+24.1%
+24.1%

More News

Read More
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
Via MarketMinute
Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗
Via Chartmill
Topics Earnings
News headline image
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
From Alkermes plc
Via Business Wire
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
From Alkermes plc
Via Business Wire
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗
Via Stocktwits
News headline image
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
From Alkermes plc
Via Business Wire
News headline image
Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes plc Announces CEO Succession Plan
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
From Alkermes plc
Via Business Wire
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
From Alkermes plc
Via Business Wire
News headline image
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Participate in Two Upcoming Investor Conferences
From Alkermes plc
Via Business Wire
News headline image
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗
Via Benzinga
News headline image
Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗
Via Investor's Business Daily

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?
Yes, Alkermes plc - Ordinary Shares is publicly traded.
What exchange does Alkermes plc - Ordinary Shares trade on?
Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alkermes plc - Ordinary Shares?
The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market
What is the current price of Alkermes plc - Ordinary Shares?
The current price of Alkermes plc - Ordinary Shares is 33.77
When was Alkermes plc - Ordinary Shares last traded?
The last trade of Alkermes plc - Ordinary Shares was at 04/16/26 04:00 PM ET
What is the market capitalization of Alkermes plc - Ordinary Shares?
The market capitalization of Alkermes plc - Ordinary Shares is 5.61B
How many shares of Alkermes plc - Ordinary Shares are outstanding?
Alkermes plc - Ordinary Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.